Soligenix Receives New Coverage from Analysts at Maxim Group (SNGX)
Analysts at Maxim Group assumed coverage on shares of Soligenix (NASDAQ:SNGX) in a research report issued to clients and investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective indicates a potential upside of 48.51% from the stock’s previous close.
Soligenix (NASDAQ:SNGX) opened at 2.02 on Tuesday. Soligenix has a 52 week low of $0.37 and a 52 week high of $2.20. The stock has a 50-day moving average of $1.70 and a 200-day moving average of $1.47. The company’s market cap is $38.4 million.
Separately, analysts at Zacks reiterated an “outperform” rating on shares of Soligenix (NASDAQ:SNGX) in a research note to investors on Monday, August 12th. They now have a $4.50 price target on the stock.
Soligenix, Inc is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.